{"schema_version":"secwatch.filing_event.v1","accession":"0000914475-25-000034","form_type":"8-K","ticker":"NBIX","cik":"0000914475","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2025-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.787317+00:00","generated_at":"2026-05-27T02:13:21.620505+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Neurocrine reports Q4 INGREZZA sales $615M (+23% YoY); 2025 guidance $2.5-2.6B","bullets":["INGREZZA net product sales $2.3B for FY2024, up 26% YoY; Q4 sales $615M (+23% YoY).","CRENESSITY (crinecerfont) approved Dec 2024 for classic CAH; initial Q4 sales $2M.","Non-GAAP diluted EPS Q4 $1.69 vs $1.54 prior year; GAAP EPS $1.00 vs $1.44 (higher stock-based comp).","2025 INGREZZA sales guidance $2.5-2.6B; Phase 3 osavampator and NBI-568 starting H1 2025.","Completed $300M ASR program in Feb 2025, repurchased ~2.3M shares; cash $1.816B."],"urls":{"canonical":"https://secwatch.observer/filing/0000914475-25-000034","json":"https://secwatch.observer/filing/0000914475-25-000034.json","markdown":"https://secwatch.observer/filing/0000914475-25-000034.md","text":"https://secwatch.observer/filing/0000914475-25-000034.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000034/0000914475-25-000034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/914475/000091447525000034/nbix-20250206.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T02:13:21.620505+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}